EHA 2021 | Optimizing chemotherapy combinations for AML

Name: Optimizing chemotherapy combinations for AML
Uploaded: 2021-06-14T00:00:00Z
Duration: 45 s
Description: Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, comments on the optimization of chemotherapy combinations for the treatment of acute myeloid leukemia (AML), highlighting the importance of considering the safety profile. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Stéphane de Botton • 14 Jun 2021

EHA 2021

Acute Myeloid Leukemia Leukemia Ivosidenib

Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, comments on the optimization of chemotherapy combinations for the treatment of acute myeloid leukemia (AML), highlighting the importance of considering the safety profile. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.